SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 8-K/A
                                Amendment No. 2

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                          Date of Report: May 23, 2006
                        (Date of earliest event reported)

                                VASOMEDICAL, INC.
             (Exact name of registrant as specified in its charter)


    Delaware                       0-18105                   11-2871434
--------------------------------------------------------------------------------
(State or other                  (Commission                (IRS Employer
 jurisdiction of                 File Number)               Identification
 incorporation)                                                Number)


180 Linden Avenue, Westbury, New York                          11590
-------------------------------------                          -----
(Address of principal executive offices)                    (Zip Code)



Registrant's telephone number including area code          (516) 997-4600
                                                           --------------


                                 Not applicable
          (Former name or former address, if changed since last report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b)

[ ] Pre-commencement  communications  pursuant to Rule 13e-4c under the Exchange
Act (17 CFR 240.13e-4c)




Item 4.01         Changes in Registrant's Certifying Accountant.

     (a) At a  meeting  held on May 23,  2006,  the  Board of  Directors  of the
Company,  at the recommendation of its Audit Committee,  approved the engagement
of MillerEllin & Company,  LLP as its  independent  auditors for the fiscal year
ended May 31, 2006,  dismissing  the firm of Grant  Thornton LLP.  MillerEllin &
Company, LLP accepted this engagement on May 23, 2006.

     The reports of Grant Thornton LLP on the Company's financial statements for
the past two fiscal years did not contain an adverse  opinion or a disclaimer of
opinion and were not qualified or modified as to  uncertainty,  audit scope,  or
accounting principles.

     In connection  with the audits of the Company's  financial  statements  for
each of the two fiscal years ended May 31, 2004 and 2005,  and in the subsequent
interim periods,  there were no disagreements with Grant Thornton on any matters
of accounting  principles  or  practices,  financial  statement  disclosure,  or
auditing  scope and procedures  which,  if not resolved to the  satisfaction  of
Grant  Thornton LLP,  would have caused Grant  Thornton LLP to make reference to
the matter in their report.

     The Company has  requested  Grant  Thornton LLP to furnish it with a letter
addressed to the Commission  stating whether it agrees with the above statements
which the Company will file as an exhibit in this form upon its receipt.

     (b) The  Company  has not had any  discussions  nor  received  any  written
opinion or oral  advice  from  MillerEllin  &  Company,  LLP during the two most
recent fiscal years and any subsequent interim period with respect to either the
application  of  accounting  principles  to  a  specified  transaction,   either
completed or proposed, or as to the type of audit opinion that might be rendered
on the Company's financial statements.


Item 9.01         Financial Statements and Exhibits

     (c)  Exhibits

          16 - Letter from Grant Thornton LLP





                                   SIGNATURES

     Pursuant to the  requirements  of the  Securities  Exchange Act of 1934, as
amended,  the  Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

                                   VASOMEDICAL, INC.


                                   By:  /s/ Thomas W. Fry
                                        ----------------------------------------
                                        Thomas W. Fry
                                        Chief Financial Officer


Dated:   June 5, 2006